Daiichi Sankyo Company, Limited (4568.T) Stock
Daiichi Sankyo Company, Limited

Company profile
Daiichi Sankyo reported revenue of 1.89 trillion JPY for fiscal year 2025, up 17.8% from fiscal year 2024, and net income of 295.76 billion JPY. That is a net profit margin of 15.7% for fiscal year 2025. United States of America was its largest region in fiscal year 2025, with 34% of revenue. Our analysis of its filings shows revenue growing from 1.28 trillion JPY in fiscal year 2023 to 1.89 trillion JPY in fiscal year 2025, 21.5% a year on average. Daiichi Sankyo reports about 20,171 full-time employees.
What stands out
- It spent 435.97 billion JPY on research and development in fiscal year 2025, 23.1% of its revenue.
- Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended March 31, 2025.
About Daiichi Sankyo Company, Limited
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.
Largest shareholders
- Nippon Life Insurance Co.3.82%
- Capital Research & Management Co. (Global Investors)3.60%
- Daiichi Sankyo Company, Limited3.25%
- Asset Management One Co., Ltd.3.01%
- Amova Asset Management Co., Ltd.2.36%
Share of the company, as of September 25, 2026
Leadership
- Hiroyuki Okuzawa — President, CEO & Representative Director, 63
- Tomohiro Kodama — Senior Executive Officer, Head of Global Corporate Planning & Management and CFO
- Takashi Matsumoto — Sr. Exec Ofcr, Chief Corp Affairs Ofcr, Head of Global Corp Affairs & HR, CHRO & Director, 61
- Tetsuya Ohira — Corporate Officer, Head of Business Transformation & CTO
- Matt Allegrucci — Head of Global Compliance & Risk Management and Chief Compliance Officer
How much revenue does Daiichi Sankyo make?
Daiichi Sankyo reported 1.89 trillion JPY in revenue for fiscal year 2025, up 17.8% from 1.60 trillion JPY in fiscal year 2024.
Where does Daiichi Sankyo make most of its revenue?
United States of America: 34% of revenue by region in fiscal year 2025, followed by Japan (31%).
What companies are similar to Daiichi Sankyo?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Chugai Pharmaceutical Co., Ltd. (4519.T), Otsuka Holdings Co., Ltd. (4578.T), Astellas Pharma Inc. (4503.T), Eisai Co., Ltd. (4523.T).
How has Daiichi Sankyo's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 962.52 billion JPY; FY2022, 1.04 trillion JPY; FY2023, 1.28 trillion JPY; FY2024, 1.60 trillion JPY; FY2025, 1.89 trillion JPY.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Daiichi Sankyo Company, Limited (4568.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4568.T